- Global Pharma News & Resources

Asthma+me Self-care Solution for Children and Young People With Asthma, Launched by Aseptika (Activ8rlives)

Asthma+me Self-care Solution for Children and Young People With Asthma, Launched by Aseptika (Activ8rlives)

PR Newswire

ST IVES, England, October 30, 2018

ST IVES, England, October 30, 2018 /PRNewswire/ --

1.1 million children in the UK have Asthma. During 2015-2016, 21 children died from asthma attacks. It was reported that 19 of these deaths could have been prevented.

     (Photo: )

For most children, asthma is well controlled through by GP's and asthma nurses. But children with moderate-to-severe asthma require treatment and support from specialist paediatric centres in major hospitals. These are being overwhelmed by the growing demand.

Asthma+me[TM] is a new solution developed by UK company Aseptika in partnership with Sheffield Children's Hospital to free up valued NHS resources in these specialist centres.

Asthma+me has been designed to support the whole family in managing their child's asthma, providing the tools for both parents and Paediatricians to monitor their condition remotely.

Bluetooth connected monitors record lung-function; medication diaries track and provide reminders of due medications and repeat prescriptions. There are also pollution, weather and pollen alerts and children can earn points towards prizes or treats as motivation to adhere to the daily Care Plan and taking their medication as prescribed.

Regularly taking inhaler medication is particularly critical to avoiding asthma attacks. Asthma+me incorporates a Bluetooth-connected inhaler tracker - PUFFClicker[TM] which counts and records doses. It supports correct inhaler technique using built-in accelerometer to confirm inhaler shaking. Activ8rlives PUFFClicker uses a simple accessory to ensure that it fits pressurised metered-dose inhalers most frequently prescribed to children, e.g. preventer inhalers (Seretide Evohaler®, Flixotide Evohaler®, Clenil® Modulite®) and reliever inhalers Salbutamol (Ivax Salamol®, Ventolin® Evohaler®).

Asthma+me App and PUFFClicker are both approved medical devices (Class 1) by UK regulatory authorities and are undergoing feasibility trials for use by NHS.

Professor Heather Elphick , Consultant Paediatric Respiratory Medicine at Sheffield Children's Hospital NHS Foundation Trust and Lead for Children and Young People's NIHR Medtech and In vitro diagnostic Co-operative:

"Sheffield Children's Hospital is treating an increasing number of children with moderate-to-severe asthma who need to take time-off from school with their parents to attend our outpatient clinics here. We must free the time of front-line staff wherever we can. We have worked directly with Aseptika to co-develop a solution as an alternative to outpatient appointments, building skills and good management techniques which will stay with them when they reach 18 years of age and transfer to adult services to help meet demand."

Asthma+me App and PUFFClicker are available for sale from and App stores (Apple, Google and Amazon).

For more information, please contact Jessica Auton on 01480-352821 or email

Editor Details

Last Updated: 30-Oct-2018